CTOs on the Move

Novation

www.novationco.com

 
Founded in 1998, Novation is the leading health care supply chain expertise, analytics and contracting company for the more than 100,000 members of VHA Inc. and UHC, two national health care alliances, Children's Hospital Association, an alliance of the nation's leading pediatric facilities, and Provista, LLC. Novation provides alliance members with sourcing services, as well as information and data services. Based in Irving, Texas, Novation develops and manages competitive contracts with more than 600 suppliers. VHA, UHC, Children’s Hospital Association, and Provista members used Novation contracts to purchase more than $43 billion in 2012.
  • Number of Employees: 100-250
  • Annual Revenue: $50-100 Million

Executives

Name Title Contact Details

Similar Companies

Atlantic Medical Imaging

Atlantic Medical Imaging is a quality-driven medical imaging practice committed to clinical excellence by providing innovative service and compassionate care that exceeds expectations.

Molecular Bio-Products

Molecular Bio-Products is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Sempre Health

Sempre Health is bringing behavior-based, individualized copays to healthcare. Today, we work with health plans and pharma manufacturers to dynamically adjust copays based on individual adherence and behavior, seamlessly at the point of fill.

Cal eConnect

Cal eConnect serves as the State's governance entity for health information exchange. As such, Cal eConnect is responsible for meeting requirements set forth in the State's grant agreement with the federal Office of the National Coordinator for Health Information Technology (ONC).

OncoGenex

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical Industries Ltd. have entered a global collaboration and licensing agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer and in patients with advanced, unresectable non-small cell lung cancer. Apatorsen is in Phase 2 clinical development and OGX-225 is currently in pre-clinical development.